Skip to main content

Table 2 Demographics of the study populations

From: Indirect comparison of intravenous vs. subcutaneous C1-inhibitor placebo-controlled trials for routine prevention of hereditary angioedema attacks

 

COMPACT study

C1-INH(SC)

60 IU/kg

(N = 45)

CHANGE study

C1-INH(IV)

1000 U

(N = 22)

Age, y

 Mean (SD)

36.8 (14.9)

38.1 (17.2)

 Median (range)

35.0 (14, 72)

38.5 (9, 73)

Gender, n (%)

 Female

32 (71.1)

20 (90.9)

 Male

13 (28.9)

2 (9.1)

Race, n (%)

 White

44 (97.8)

21 (95.5)

 Black/African-American

1 (2.2)

1 (4.5)

 Asian

0

0

 Other

0

0

Weight, kg

 Mean (SD)

80.2 (24.6)

73.4 (18.9)

 Median (range)

78.0 (43.0, 156.8)

69.3 (37.6, 113.9)

HAE type, n (%)

 Type 1

37 (82.2)

18 (81.8)

 Type 2

8 (17.8)

4 (18.2)

  1. HAE hereditary angioedema, IU international units, IV intravenous, SC subcutaneous, SD standard deviation, U units, y years